Anthony J. Cleare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anthony J. Cleare has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Simon Wessely
King's Centre for Military Health Research, Department of Psychological Medicine, King's College London, London, UK
4 shared publications - Veronica O'Keane
Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland
3 shared publications A. J. Bond
Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
2 shared publicationsA.S. Papadopoulos
2 shared publications- Amanda Roberts
University of Lincoln
2 shared publications C.M. Pariante
2 shared publications
Latest Publications
- 1 October 2014
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 24, S402-S403
P.2.b.040 MR and GR balance predicts treatment outcome in treatment resistant depression
- 1 October 2014
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 24, S402-S403
P.2.b.040 MR and GR balance predicts treatment outcome in treatment resistant depression
- 31 August 2010
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 20, S351-S352
P.2.a.031 Prednisolone suppression test, but not dexamethasone predicts outcome in treatment resistant depression
- 31 August 2010
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 20, S351-S352
P.2.a.031 Prednisolone suppression test, but not dexamethasone predicts outcome in treatment resistant depression
- 17 July 2009
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 40 (3) , 515-522
Does hypocortisolism predict a poor response to cognitive behavioural therapy in chronic fatigue syndrome?
Background: There is evidence that patients with chronic fatigue syndrome (CFS) have mild hypocortisolism. The clinical significance of this is unclear. We aimed to determine whether hypocortisolism exerted any effect on the response of CFS to cognitive behavioural therapy (CBT).Method: We measured 24-h urinary free cortisol (UFC) in 84 patients with Centers for Disease Control and Prevention (CDC)-defined CFS (of whom 64 were free from psychotropic medication) who then received CBT in a specialist, tertiary out-patient clinic as part of their usual clinical care. We also measured salivary cortisol output from 0800 to 2000 h in a subsample of 56 psychotropic medication-free patients.Results: Overall, 39% of patients responded to CBT after 6 months of treatment. Lower 24-h UFC output was associated with a poorer response to CBT but only in psychotropic medication-free patients. A flattened diurnal profile of salivary cortisol was also associated with a poor response to CBT.Conclusions: Low cortisol is of clinical relevance in CFS, as it is associated with a poorer response to CBT. Hypocortisolism could be one of several maintaining factors that interact in the persistence of CFS.
- 17 July 2009
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 40 (3) , 515-522
Does hypocortisolism predict a poor response to cognitive behavioural therapy in chronic fatigue syndrome?
Background: There is evidence that patients with chronic fatigue syndrome (CFS) have mild hypocortisolism. The clinical significance of this is unclear. We aimed to determine whether hypocortisolism exerted any effect on the response of CFS to cognitive behavioural therapy (CBT).Method: We measured 24-h urinary free cortisol (UFC) in 84 patients with Centers for Disease Control and Prevention (CDC)-defined CFS (of whom 64 were free from psychotropic medication) who then received CBT in a specialist, tertiary out-patient clinic as part of their usual clinical care. We also measured salivary cortisol output from 0800 to 2000 h in a subsample of 56 psychotropic medication-free patients.Results: Overall, 39% of patients responded to CBT after 6 months of treatment. Lower 24-h UFC output was associated with a poorer response to CBT but only in psychotropic medication-free patients. A flattened diurnal profile of salivary cortisol was also associated with a poor response to CBT.Conclusions: Low cortisol is of clinical relevance in CFS, as it is associated with a poorer response to CBT. Hypocortisolism could be one of several maintaining factors that interact in the persistence of CFS.
- 1 May 2005
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 67 (3) , 433-440
24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome
Objectives: Disturbances of neuroendocrine function, particularly the hypothalamo–pituitary–adrenal (HPA) axis, have been implicated in the pathophysiology of chronic fatigue syndrome (CFS). However, few studies have attempted to measure blood levels of pituitary or adrenal hormones across a whole 24-hour period in CFS, and those that did so have used infrequent sampling periods. Our aim was to assess 24-hour pituitary and adrenal function using frequent blood sampling. Methods: We recruited 15 medication-free patients with CFS without comorbid psychiatric disorder and 10 healthy control subjects. Blood samples were collected over 24 hours and assayed for cortisol, corticotropin (ACTH), growth hormone (GH), and prolactin (PRL) levels on an hourly basis during daytime hours (10 am to 10 pm) and every 15 minutes thereafter (10 pm to 10 am). Results: Repeated-measures analyses of variance were undertaken using hormone levels averaged over 2-hour blocks to smooth curves by reducing the influence of sample timing relative to secretory burst. For ACTH, there was both a main effect of group, suggesting reduced mean ACTH secretion in patients with CFS over the whole monitoring period, and a group-by-time interaction, suggesting a differential pattern of ACTH release. Post hoc analysis showed reduced ACTH levels in CFS during the 8 am to 10 am period. In contrast, there were no significant abnormalities in the levels of cortisol, GH, and PRL in patients with CFS over the full cycle compared with control subjects. Cosinor analysis found no differences in the cortisol circadian rhythm parameters, but the ACTH rhythm did differ, patients with CFS showing an earlier acrophase. Conclusions: Patients with CFS demonstrated subtle alterations in HPA axis activity characterized by reduced ACTH over a full circadian cycle and reduced levels during the usual morning physiological peak ACTH secretion. This provides further evidence of subtle dysregulation of the HPA axis in CFS. Whether this dysregulation is a primary feature of the illness or instead represents a biologic effect secondary to having the illness itself remains unclear. PRL = prolactin; GH = growth hormone; ACTH = corticotrophin; CFS = chronic fatigue syndrome; HPA = hypothalamo–pituitary–adrenal; BMI = body mass index; CDC = Centers for Disease Control and Prevention; DSM-IV = Diagnostic and Statistical Manual, Fourth Edition; RIA = radioimmunoassay; IRMA = immunoradiometric assay; NETRIA = North East Thames radioimmunoassay; ANOVA = analysis of variance; CV = coefficient of variance; MESOR = midline estimate statistic of rhythm; CRH = corticotrophin-releasing hormone; CI = confidence interval; SD = standard deviation.
- 1 May 2005
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 67 (3) , 433-440
24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome
Objectives: Disturbances of neuroendocrine function, particularly the hypothalamo–pituitary–adrenal (HPA) axis, have been implicated in the pathophysiology of chronic fatigue syndrome (CFS). However, few studies have attempted to measure blood levels of pituitary or adrenal hormones across a whole 24-hour period in CFS, and those that did so have used infrequent sampling periods. Our aim was to assess 24-hour pituitary and adrenal function using frequent blood sampling. Methods: We recruited 15 medication-free patients with CFS without comorbid psychiatric disorder and 10 healthy control subjects. Blood samples were collected over 24 hours and assayed for cortisol, corticotropin (ACTH), growth hormone (GH), and prolactin (PRL) levels on an hourly basis during daytime hours (10 am to 10 pm) and every 15 minutes thereafter (10 pm to 10 am). Results: Repeated-measures analyses of variance were undertaken using hormone levels averaged over 2-hour blocks to smooth curves by reducing the influence of sample timing relative to secretory burst. For ACTH, there was both a main effect of group, suggesting reduced mean ACTH secretion in patients with CFS over the whole monitoring period, and a group-by-time interaction, suggesting a differential pattern of ACTH release. Post hoc analysis showed reduced ACTH levels in CFS during the 8 am to 10 am period. In contrast, there were no significant abnormalities in the levels of cortisol, GH, and PRL in patients with CFS over the full cycle compared with control subjects. Cosinor analysis found no differences in the cortisol circadian rhythm parameters, but the ACTH rhythm did differ, patients with CFS showing an earlier acrophase. Conclusions: Patients with CFS demonstrated subtle alterations in HPA axis activity characterized by reduced ACTH over a full circadian cycle and reduced levels during the usual morning physiological peak ACTH secretion. This provides further evidence of subtle dysregulation of the HPA axis in CFS. Whether this dysregulation is a primary feature of the illness or instead represents a biologic effect secondary to having the illness itself remains unclear. PRL = prolactin; GH = growth hormone; ACTH = corticotrophin; CFS = chronic fatigue syndrome; HPA = hypothalamo–pituitary–adrenal; BMI = body mass index; CDC = Centers for Disease Control and Prevention; DSM-IV = Diagnostic and Statistical Manual, Fourth Edition; RIA = radioimmunoassay; IRMA = immunoradiometric assay; NETRIA = North East Thames radioimmunoassay; ANOVA = analysis of variance; CV = coefficient of variance; MESOR = midline estimate statistic of rhythm; CRH = corticotrophin-releasing hormone; CI = confidence interval; SD = standard deviation.
- 1 February 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 57 (3) , 239-246
Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635
- 1 February 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 57 (3) , 239-246
Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635
- 1 November 2004
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 57 (5) , 423-425
Stress and fibromyalgia—what is the link?
- 1 November 2004
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 57 (5) , 423-425
Stress and fibromyalgia—what is the link?
- 1 July 2004
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 29 (6) , 724-732
Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome
- 1 July 2004
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 29 (6) , 724-732
Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome
- 1 March 2004
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 15 (2) , 55-59
The HPA axis and the genesis of chronic fatigue syndrome
- 1 March 2004
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 15 (2) , 55-59
The HPA axis and the genesis of chronic fatigue syndrome
- Open Access
- 1 February 2004
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 184 (2) , 136-141
Salivary cortisol response to awakening in chronic fatigue syndrome
Background: There is accumulating evidence of hypothalamic–pituitary–adrenal (HPA) axis disturbances in chronic fatigue syndrome (CFS). The salivary cortisol response to awakening has been described recently as a non-invasive test of the capacity of the HPA axis to respond to stress. The results of this test correlate closely with those of more invasive dynamic tests reported in the literature; furthermore, it can be undertaken in a naturalistic setting.Aims: To assess the HPA axis using the salivary cortisol response to awakening in CFS.Method: We measured salivary cortisol upon awakening and 10, 20, 30 and 60 min afterwards in 56 patients with CFS and 35 healthy volunteers.Results: Patients had a lower cortisol response to awakening, measured by the area under the curve.Conclusions: This naturalistic test of the HPA axis response to stress showed impaired HPA axis function in CFS.
- 1 February 2004
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 184 (2) , 136-141
Open AccessSalivary cortisol response to awakening in chronic fatigue syndrome
Background: There is accumulating evidence of hypothalamic–pituitary–adrenal (HPA) axis disturbances in chronic fatigue syndrome (CFS). The salivary cortisol response to awakening has been described recently as a non-invasive test of the capacity of the HPA axis to respond to stress. The results of this test correlate closely with those of more invasive dynamic tests reported in the literature; furthermore, it can be undertaken in a naturalistic setting.Aims: To assess the HPA axis using the salivary cortisol response to awakening in CFS.Method: We measured salivary cortisol upon awakening and 10, 20, 30 and 60 min afterwards in 56 patients with CFS and 35 healthy volunteers.Results: Patients had a lower cortisol response to awakening, measured by the area under the curve.Conclusions: This naturalistic test of the HPA axis response to stress showed impaired HPA axis function in CFS.
- 1 December 2003
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 15 (6) , 341-353
Glucocorticoids and glucocorticoid receptors: mediators of fatigue?
Fatigue is a common problem; when chronic and disabling, subjects can be categorized as having chronic fatigue syndrome (CFS). Whilst it is most likely a multifactorial condition of biopsychosocial origin, the nature of the pathophysiological component remains unclear. There has been a wealth of interest in the possible hypothalamo–pituitary–adrenal (HPA) axis dysfunction in CFS, and whether such changes may mediate fatigue. On balance, there appears to be reduced cortisol output in a proportion of patients, together with heightened negative feedback and glucocorticoid receptor function. There is evidence for impaired adrenocorticotropic hormone (ACTH) and cortisol responses to a variety of challenges. However, there is no evidence for a specific or uniform dysfunction of the HPA axis. Evidence that these changes may be related to symptom production comes from randomized controlled trials of glucocorticoid replacement therapy, which have shown improvements in fatigue and disability. Given the many factors that may impinge on the HPA axis in CFS, such as inactivity, sleep disturbance, psychiatric comorbidity, medication and ongoing stress, it seems likely that there is not a single or specific change to the HPA axis in CFS and that the observed HPA axis disturbances are of multifactorial etiology. This is further supported by a comparison of neuroendocrine findings in other conditions in which fatigue is prominent, showing both similarities and differences with the pattern in CFS.
- 1 December 2003
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 15 (6) , 341-353
Glucocorticoids and glucocorticoid receptors: mediators of fatigue?
Fatigue is a common problem; when chronic and disabling, subjects can be categorized as having chronic fatigue syndrome (CFS). Whilst it is most likely a multifactorial condition of biopsychosocial origin, the nature of the pathophysiological component remains unclear. There has been a wealth of interest in the possible hypothalamo–pituitary–adrenal (HPA) axis dysfunction in CFS, and whether such changes may mediate fatigue. On balance, there appears to be reduced cortisol output in a proportion of patients, together with heightened negative feedback and glucocorticoid receptor function. There is evidence for impaired adrenocorticotropic hormone (ACTH) and cortisol responses to a variety of challenges. However, there is no evidence for a specific or uniform dysfunction of the HPA axis. Evidence that these changes may be related to symptom production comes from randomized controlled trials of glucocorticoid replacement therapy, which have shown improvements in fatigue and disability. Given the many factors that may impinge on the HPA axis in CFS, such as inactivity, sleep disturbance, psychiatric comorbidity, medication and ongoing stress, it seems likely that there is not a single or specific change to the HPA axis in CFS and that the observed HPA axis disturbances are of multifactorial etiology. This is further supported by a comparison of neuroendocrine findings in other conditions in which fatigue is prominent, showing both similarities and differences with the pattern in CFS.